Cancer News and Research

Latest Cancer News and Research

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Neogenix Oncology announced today that Dr. Luis Diaz of The Johns Hopkins University Hospital will present data from Ensituximab, the company's novel, therapeutic antibody to treat pancreatic and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Gastrointestinal Cancers Symposium to be held January 20-22, 2011 at the Moscone Center in San Francisco, CA, USA.

19 Jan 2011

Theraclone, Pfizer enter multi-year research and development collaboration

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that they have entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theraclone's I-STAR™ technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

19 Jan 2011

OXiGENE reaches agreement with warrant holders for warrant exchange

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, has entered into separate Warrant Exchange Agreements with each of the holders of outstanding warrants originally issued in March 2010 to eliminate all of such warrants having "ratchet" price-based anti-dilution protection features in exchange for shares of Company common stock and a lower number of warrants having no price based anti-dilution protections.

19 Jan 2011

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).

19 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

Collaborative study may lead to improved influenza vaccine and vaccines for other respiratory virus infections

A collaborative project between researchers at the Trudeau Institute and their colleagues at St. Jude Children's Research Hospital in Memphis, Tenn., offers new insights that may lead to an improved strategy to protect against the influenza virus and other viruses that infect the respiratory tract.

19 Jan 2011

Patients with varied patchwork of genetic faults in tumours have worse outcomes

Cancer Research UK scientists have discovered that cervical cancer patients who have a mixture of different genetic faults in their tumour at the start of treatment may be more likely to relapse, according to a study published in the British Journal of Cancer today.

19 Jan 2011

CareCore National and D3 partner to accelerate implementation of cancer care pathways

To improve quality and contain rising costs in cancer care, CareCore National and D3, an affiliate of UPMC, have formed a new company to accelerate implementation of cancer care pathways.

19 Jan 2011

Europe's leading oncology organisations receive €12 million grant to streamline cross border research

Europe's leading oncology organisations are combining forces in the global fight against cancer. The project, EurocanPlatform, has received €12 million from the European Union to streamline cross border research. The project will find moreeffective ways to ensure the prevention, early discovery and treatment of different forms of cancer.

19 Jan 2011

UNC scientists discover how chaperone enzyme plays a key role in cells' ability to tolerate DNA damage

UNC scientists who study how cells repair damage from environmental factors like sunlight and cigarette smoke have discovered how a "chaperone" enzyme plays a key role in cells' ability to tolerate the DNA damage that leads to cancer and other diseases.

19 Jan 2011

Health care reform should mend disconnect between USPSTF recommendations and Medicare coverage

Health care reform should be able to mend a disconnect that has existed between the recommendations of the U.S. Preventive Services Task Force (USPSTF), a task force charged by the government to review clinical preventive health services for older adults, and Medicare coverage for those services, a new UCLA-led study finds.

19 Jan 2011

MD Anderson experts create plan to guide women on healthy behaviors

"A woman's life changes at every decade and so does her body," says Therese Bevers, M.D., medical director of MD Anderson's Cancer Prevention Center. "And, just as a woman sets personal and work-related milestones, she also should set health goals for every stage of life."

19 Jan 2011

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

19 Jan 2011

Kidney transplant surgeon receives Loyola's Spirit of Martin Luther King Jr. Award

Each year, Loyola University Health System presents its prestigious Spirit of Martin Luther King Jr. Award to an employee who provides inspirational service to others in the spirit of the slain civil rights leader.

19 Jan 2011

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUS study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy.

19 Jan 2011

New study provides insight into developing therapeutics for airway disease

Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.

19 Jan 2011

New patented technique offers unprecedented view of DNA damage

New technology providing the first view of DNA damage throughout the entire human genome developed by Cardiff University scientists could offer a valuable new insight into the development and treatment of conditions like cancer.

19 Jan 2011

RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma

Genentech, a member of the Roche Group, today announced that BRIM3, a Phase III clinical study of RG7204, met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

19 Jan 2011

New project on developing countermeasures for natural and intentional exposure to disease pathogens

Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency (DARPA) and the Army Research Office (ARO) to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens. The ultimate goal is to develop a viable countermeasure to an unknown pathogen within seven days of receiving it in a laboratory.

19 Jan 2011

Positive preliminary results from Soligenix's SGX202 in GARS model

Soligenix, Inc., a late-stage biopharmaceutical company, announced today promising preliminary results from a preclinical study of SGX202 in a canine gastrointestinal acute radiation syndrome model.

19 Jan 2011

Cancer News and Research

Latest Cancer News and Research

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Theraclone, Pfizer enter multi-year research and development collaboration

OXiGENE reaches agreement with warrant holders for warrant exchange

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

National Jewish Health issued method patent for desensitizing B cells

Collaborative study may lead to improved influenza vaccine and vaccines for other respiratory virus infections

Patients with varied patchwork of genetic faults in tumours have worse outcomes

CareCore National and D3 partner to accelerate implementation of cancer care pathways

Europe's leading oncology organisations receive €12 million grant to streamline cross border research

UNC scientists discover how chaperone enzyme plays a key role in cells' ability to tolerate DNA damage

Health care reform should mend disconnect between USPSTF recommendations and Medicare coverage

MD Anderson experts create plan to guide women on healthy behaviors

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

Kidney transplant surgeon receives Loyola's Spirit of Martin Luther King Jr. Award

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

New study provides insight into developing therapeutics for airway disease

New patented technique offers unprecedented view of DNA damage

RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma

New project on developing countermeasures for natural and intentional exposure to disease pathogens

Positive preliminary results from Soligenix's SGX202 in GARS model

Industry Focus eBook - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in